瑞舒伐他汀对急性冠脉综合征患者IL-6、GMP-140、BNP及心功能的影响

Effects of rosuvastatin on serum IL-6,GMP-140,BNP and heart function on treatment of acute coronary syndromes

目的观察瑞舒伐他汀治疗急性冠脉综合征患者白细胞介素-6(IL-6)、血浆α-颗粒膜蛋白(GMP-140)、脑钠素(BNP)和心功能的变化。方法 80例急性冠脉综合征患者随机分为两组,对照组40例给予常规治疗;治疗组40例在对照组治疗的基础上加用瑞舒伐他汀口服。两组疗程均为32周。结果治疗32周治疗组血清IL-6、GMP-140和BNP显著低于对照组(P<0.01),左室射血分数(LVEF)明显改善(P<0.01),对照组无明显变化。结论瑞舒伐他汀治疗急性冠脉综合症患者可以使血清IL-6、GMP-140和BNP水平显著下降,减轻炎症反应,抑制血小板活化,稳定动脉粥样硬化斑块,改善心功能。

Objective To observe the clinical effect of rosuvastatin plasma IL-6, GMP-140, BNP levels and heart function in patients with acute eoronary syndromes. Methods 80 cases of acute eoronary syndromes patients were randomly divided into two groups.40 ea- ses in control group were given conventional treatment while 40 cases in treatment group were given oral rosuvastatin based on the con- trol group treatment. Both groups were treated for 32 weeks. Results After the treatment, in treatment group, serum IL-6 、GMP-140 and BNP were significantly lower than those in the control group（P 〈 0.01）. LVEF was increased in treatment group,while these were not significant change in treatment group. Conclusions Rosuvastatin treatment of acute eoronat7 syndromes can have a significant re- duction in sermn IL-6, GMP-140 and BNP level, reduce inflammation reaction, inhibit activation of platelet, stable atheroselerotie plaque, and improve heart function.